For the year ending 2025-12-31, AVTX made $59K in revenue. -$78,191K in net income. Net profit margin of -132527.12%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenues, net | 59 | |||
| Cost of product sales | 0 | |||
| Research and development | 50,084 | |||
| Acquired in-process research and development | 0 | |||
| General and administrative | 22,900 | |||
| Total operating expenses | 72,984 | |||
| Loss from operations | -72,925 | |||
| Change in fair value of derivative liability | -9,520 | |||
| Interest income, net | 4,351 | |||
| Excess of initial warrant fair value over private placement proceeds | 0 | |||
| Change in fair value of warrant liability | 0 | |||
| Private placement transaction costs | 0 | |||
| Total other (expense) income, net | -5,169 | |||
| Loss before income taxes | -78,094 | |||
| Income tax expense | 165 | |||
| Net loss | -78,259 | |||
| Unrealized income on investments, net | 68 | |||
| Comprehensive loss | -78,191 | |||
| Basic EPS | -5.84 | |||
| Diluted EPS | -5.84 | |||
| Basic Average Shares | 13,404,830 | |||
| Diluted Average Shares | 13,404,830 | |||
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)